Dimensional Fund Advisors LP Grows Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Dimensional Fund Advisors LP boosted its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 86.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 134,353 shares of the company’s stock after purchasing an additional 62,143 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.17% of Trevi Therapeutics worth $553,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of TRVI. Barclays PLC increased its holdings in Trevi Therapeutics by 180.8% in the 3rd quarter. Barclays PLC now owns 95,232 shares of the company’s stock worth $319,000 after buying an additional 61,317 shares during the period. JPMorgan Chase & Co. raised its position in shares of Trevi Therapeutics by 220.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company’s stock worth $336,000 after purchasing an additional 69,167 shares during the last quarter. SG Americas Securities LLC lifted its holdings in Trevi Therapeutics by 14.5% in the 4th quarter. SG Americas Securities LLC now owns 26,792 shares of the company’s stock valued at $110,000 after purchasing an additional 3,387 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Trevi Therapeutics in the 4th quarter valued at $67,000. Finally, Bank of New York Mellon Corp lifted its holdings in Trevi Therapeutics by 2.1% in the 4th quarter. Bank of New York Mellon Corp now owns 140,219 shares of the company’s stock valued at $578,000 after purchasing an additional 2,935 shares in the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

Insider Activity

In other news, CEO Jennifer L. Good sold 5,263 shares of the firm’s stock in a transaction dated Friday, March 21st. The stock was sold at an average price of $6.58, for a total value of $34,630.54. Following the transaction, the chief executive officer now directly owns 213,313 shares in the company, valued at $1,403,599.54. This trade represents a 2.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Farrell Simon sold 81,313 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the transaction, the insider now owns 76,900 shares in the company, valued at approximately $519,075. This trade represents a 51.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 18.30% of the company’s stock.

Trevi Therapeutics Price Performance

Shares of TRVI stock opened at $6.50 on Friday. The business’s fifty day moving average price is $6.29 and its 200 day moving average price is $4.63. Trevi Therapeutics, Inc. has a 1-year low of $2.30 and a 1-year high of $7.39. The firm has a market capitalization of $649.30 million, a PE ratio of -14.77 and a beta of 0.62.

Trevi Therapeutics (NASDAQ:TRVI) last posted its earnings results on Tuesday, May 6th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.04. Equities research analysts expect that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on TRVI. Raymond James upgraded Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price target for the stock from $9.00 to $29.00 in a report on Monday, March 10th. B. Riley reiterated a “buy” rating and issued a $20.00 price objective (up previously from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. D. Boral Capital restated a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Oppenheimer boosted their target price on Trevi Therapeutics from $12.00 to $20.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $12.50 price objective on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Seven analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Trevi Therapeutics has a consensus rating of “Buy” and an average price target of $17.56.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.